- BDX Ticker
- πΊπΈ NYSE Exchange
- 76,032 Employees
- π Health Care Sector
- π©Ί Health Care Equipment & Supplies Industry
- Vincent A. Forlenza CEO
Financial statements β Becton, Dickinson & Co
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 β 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
17B | 17B | 16B | 12B | 12B |
| Cost Of Revenue |
|
9.5B | 9B | 8.7B | 6.2B | 6.5B |
| Gross Profit |
|
7.6B | 8.3B | 7.3B | 5.9B | 6B |
| Research and Development |
|
1.1B | 1.1B | 1B | 770M | 830M |
| Selling General and Admin |
|
4.3B | 4.3B | 4B | 2.9B | 3B |
| Operating Expense |
|
15B | 15B | 14B | 9.9B | 10B |
| Operating Income |
|
1.8B | 2.2B | 2.2B | 2.2B | 2.2B |
| Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
| EBIT |
|
1.8B | 2.2B | 2.2B | 2.2B | 2.2B |
| Interest Income |
|
520M | 630M | 640M | 450M | 370M |
| Pretax Income |
|
990M | 1.2B | 1.2B | 980M | 1.1B |
| Income Tax |
|
110M | -57M | 860M | -120M | 97M |
| Minority Interest |
|
0 | 0 | 0 | 0 | 0 |
| Net Income |
|
770M | 1.1B | 160M | 1B | 980M |
| Net Income Basic |
|
770M | 1.1B | 160M | 1B | 980M |
| 20 β 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
2.8B | 570M | 1.2B | 14B | 1.6B |
| Short term investments |
|
890M | 1.1B | 1.3B | 870M | 820M |
| Receivables |
|
2.4B | 2.3B | 2.3B | 1.7B | 1.6B |
| Inventory |
|
2.7B | 2.6B | 2.5B | 1.8B | 1.7B |
| Other current assets |
|
890M | 1.1B | 1.3B | 870M | 820M |
| Current assets |
|
9B | 6.7B | 7.4B | 19B | 6.4B |
| Long term investments |
|
45B | 45B | 46B | 19B | 19B |
| Property plant equipment |
|
5.9B | 5.7B | 5.4B | 4.6B | 3.9B |
| Goodwill |
|
24B | 23B | 24B | 7.6B | 7.4B |
| Intangible assets |
|
14B | 15B | 16B | 5.9B | 6.4B |
| Other assets |
|
1.7B | 1.1B | 1.1B | 1B | 1.5B |
| Total assets |
|
54B | 52B | 54B | 38B | 26B |
| Accounts payable |
|
1.4B | 1.1B | 1.1B | 800M | 670M |
| Current long term debt |
|
710M | 1.3B | 2.6B | 200M | 1B |
| Other current liabilities |
|
3.8B | 3.3B | 3.5B | 2.3B | 2.7B |
| Total current liabilities |
|
5.8B | 5.7B | 7.2B | 3.3B | 4.4B |
| Long term debt |
|
17B | 18B | 19B | 19B | 11B |
| Other liabilities |
|
7.2B | 6.9B | 6.8B | 2.8B | 3B |
| Minority Interest |
|
0 | 0 | 0 | 0 | 0 |
| Total Liabilities |
|
30B | 31B | 33B | 25B | 18B |
| Common stock |
|
280M | 270M | 260M | 220M | 210M |
| Retained earning |
|
13B | 13B | 13B | 13B | 13B |
| Treasury stock |
|
-6.1B | -6.2B | -6.2B | -8.4B | -8.2B |
| Capital surplus |
|
β’ | β’ | β’ | β’ | β’ |
| Shareholder equity |
|
24B | 21B | 21B | 13B | 7.6B |
| Net tangible assets |
|
-14B | -17B | -19B | -510M | -6.1B |
| 20 β 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
770M | 1.1B | 160M | 1B | 980M |
| Depreciation |
|
2.2B | 2.3B | 2B | 1.1B | 1.1B |
| Changes in receivables |
|
53M | 26M | 580M | 130M | 0 |
| Changes in inventories |
|
160M | 130M | 630M | 99M | -240M |
| Cash change |
|
2.3B | -590M | -13B | 13B | 120M |
| Cash flow |
|
3.5B | 3.3B | 2.9B | 2.6B | 2.6B |
| Capital expenditures |
|
-810M | -960M | -900M | -730M | -690M |
| Investments |
|
β’ | β’ | β’ | β’ | β’ |
| Investing activity other |
|
β’ | β’ | β’ | β’ | β’ |
| Total investing cash flows |
|
-1.2B | -740M | -16B | -880M | -670M |
| Dividends paid |
|
β’ | β’ | β’ | β’ | β’ |
| Net borrowings |
|
14B | 18B | 19B | 3.8B | 9.2B |
| Other financing cash flows |
|
β’ | β’ | β’ | β’ | β’ |
| Cash flow financing |
|
22M | -3.2B | -58M | 11B | -1.8B |
| Exchange rate effect |
|
β’ | β’ | β’ | β’ | β’ |
Analyst Recommendations
This chart is a recommendation for investors. To provide forecasts, analysts and brokers use companies' public financial reports and speak with their employees and clients. The end result is a solution that's marked on the chart, which shows analysts' opinions at different periods of time. Move your cursor to track on what the dates the recommendations changed.
Investors shouldn't only follow analyst recommendations. Forecasts should be used to supplement existing strategies and plans. Trading based on a recommendation chart is is considered bad practice. Analyst reports should only be used in conjunction with your own analytics.
Also known as strong sell, it's a recommendation to sell a security or to liquidate an asset.
A recommendation that means a stock is expected to do slightly worse than the overall stock market return. Underperform can also be expressed as "moderate sell", "weak hold" and "underweight."
A company with a hold recommendation is expected to perform on par with comparable companies or in line with the market.
Also known as "moderate buy", "accumulate", and "overweight." Outperform is an analyst recommendation meaning a stock is expected to do slightly better than the market return.
Also known as strong buy and "on the recommended list." Needless to say, buy is a recommendation to purchase a specific security.
Also known as strong sell, it's a recommendation to sell a security or to liquidate an asset.
A recommendation that means a stock is expected to do slightly worse than the overall stock market return. Underperform can also be expressed as "moderate sell", "weak hold" and "underweight."
A company with a hold recommendation is expected to perform on par with comparable companies or in line with the market.
Also known as "moderate buy", "accumulate", and "overweight." Outperform is an analyst recommendation meaning a stock is expected to do slightly better than the market return.
Also known as strong buy and "on the recommended list." Needless to say, buy is a recommendation to purchase a specific security.
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates through two worldwide business segments: BD Medical and BD Life Sciences. The BD Medical segment produces medical devices that are used in healthcare settings. This segment product includes needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Life Sciences segment produces products for the safe collection and transport of diagnostic specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal products and services in the Life Sciences segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; plated media; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunology and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.